Hedgehog Signaling Regulates Brain Tumor‐Initiating Cell Proliferation and Portends Shorter Survival for Patients with PTEN‐Coexpressing Glioblastomas

The identification of brain tumor stem‐like cells (BTSCs) has implicated a role of biological self‐renewal mechanisms in clinical brain tumor initiation and propagation. The molecular mechanisms underlying the tumor‐forming capacity of BTSCs, however, remain unknown. Here, we have generated molecular signatures of glioblastoma multiforme (GBM) using gene expression profiles of BTSCs and have identified both Sonic Hedgehog (SHH) signaling‐dependent and ‐independent BTSCs and their respective glioblastoma surgical specimens. BTSC proliferation could be abrogated in a pathway‐dependent fashion in vitro and in an intracranial tumor model in athymic mice. Both SHH‐dependent and ‐independent brain tumor growth required phosphoinositide 3‐kinase‐mammalian target of rapamycin signaling. In human GBMs, the levels of SHH and PTCH1 expression were significantly higher in PTEN‐expressing tumors than in PTEN‐deficient tumors. In addition, we show that hyperactive SHH‐GLI signaling in PTEN‐coexpressing human GBM is associated with reduced survival time. Thus, distinct proliferation signaling dependence may underpin glioblastoma propagation by BTSCs. Modeling these BTSC proliferation mechanisms may provide a rationale for individualized glioblastoma treatment.

[1]  R. DePinho,et al.  Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Ivan Radovanovic,et al.  HEDGEHOG-GLI1 Signaling Regulates Human Glioma Growth, Cancer Stem Cell Self-Renewal, and Tumorigenicity , 2007, Current Biology.

[3]  K. Gelmon,et al.  Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin , 2007, Breast Cancer Research and Treatment.

[4]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[5]  Yuri Kotliarov,et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.

[6]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[7]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[8]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Meyerson,et al.  Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. , 2007, Cancer cell.

[10]  T. Pawson,et al.  grb2 heterozygosity rescues embryonic lethality but not tumorigenesis in pten+/- mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Paul S Mischel,et al.  Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. , 2003, Cancer research.

[12]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[13]  R. Weinberg,et al.  Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity. , 2007, Cancer research.

[14]  R. Schneider-Broussard,et al.  Prostate cancer stem/progenitor cells: Identification, characterization, and implications , 2007, Molecular carcinogenesis.

[15]  G. Fishell,et al.  Sonic hedgehog contributes to oligodendrocyte specification in the mammalian forebrain. , 2001, Development.

[16]  B. Neel,et al.  Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer , 2007, Cancer biology & therapy.

[17]  Sathish Kumar Mungamuri,et al.  Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. , 2006, Cancer research.

[18]  H. Weiner,et al.  The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. , 2001, Development.

[19]  T. Kawase,et al.  Patched and Smoothened MRNA Expression in Human Astrocytic Tumors Inversely Correlates with Histological Malignancy , 2004, Journal of Neuro-Oncology.

[20]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[21]  R. DePinho,et al.  Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. , 2002, Cancer cell.

[22]  I. Mellinghoff,et al.  Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer , 2006, Nature Medicine.

[23]  L. Ricci-Vitiani,et al.  Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.

[24]  Paul S Mischel,et al.  Identification of molecular subtypes of glioblastoma by gene expression profiling , 2003, Oncogene.

[25]  T. Mak,et al.  Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. K. Cooper,et al.  Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells , 2007, Oncogene.

[27]  M. Lohuizen,et al.  Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas , 2004, Nature.

[28]  S. Vandenberg,et al.  PDGFRα-Positive B Cells Are Neural Stem Cells in the Adult SVZ that Form Glioma-like Growths in Response to Increased PDGF Signaling , 2006, Neuron.

[29]  Y. Leea,et al.  Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target , 2006 .

[30]  D. Farkas,et al.  Isolation of cancer stem cells from adult glioblastoma multiforme , 2004, Oncogene.

[31]  Ross Tubo,et al.  Mesenchymal stem cells within tumour stroma promote breast cancer metastasis , 2007, Nature.

[32]  William A Weiss,et al.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.

[33]  Susan M. Chang,et al.  Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme , 2005, Investigational New Drugs.

[34]  Helen Baines,et al.  Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. , 2004, Cancer cell.

[35]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[36]  A. Olivi,et al.  Cyclopamine‐Mediated Hedgehog Pathway Inhibition Depletes Stem‐Like Cancer Cells in Glioblastoma , 2007, Stem cells.

[37]  A. Joyner,et al.  Gli1 is important for medulloblastoma formation in Ptc1+/− mice , 2005, Oncogene.

[38]  Joanne Chan,et al.  Sonic Hedgehog–Regulated Oligodendrocyte Lineage Genes Encoding bHLH Proteins in the Mammalian Central Nervous System , 2000, Neuron.

[39]  G. Broggi,et al.  Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells , 2006, Nature.

[40]  Hongye Liu,et al.  Olig2-Regulated Lineage-Restricted Pathway Controls Replication Competence in Neural Stem Cells and Malignant Glioma , 2007, Neuron.

[41]  D. Ito,et al.  In vivo antitumor effect of the mTOR inhibitor CCI‐779 and gemcitabine in xenograft models of human pancreatic cancer , 2006, International journal of cancer.

[42]  M. Datta,et al.  Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[43]  G. Rao,et al.  Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice , 2004, Oncogene.

[44]  D. Botstein,et al.  Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. McLendon,et al.  Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. , 2005, Molecular cancer therapeutics.

[46]  C. Creighton,et al.  A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors , 2007, Oncogene.

[47]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[48]  Susan M. Chang,et al.  Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs , 2004, Investigational New Drugs.